EZZ Life Science Holdings Limited provides skin care and consumer health products to retailers and consumers in Australia, New Zealand, Mainland China, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.51|
|52 Week High||AU$0.38|
|52 Week Low||AU$1.43|
|1 Month Change||-11.30%|
|3 Month Change||24.39%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.03%|
Recent News & Updates
|EZZ||AU Retail Distributors||AU Market|
Return vs Industry: Insufficient data to determine how EZZ performed against the Australian Retail Distributors industry.
Return vs Market: Insufficient data to determine how EZZ performed against the Australian Market.
Stable Share Price: EZZ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EZZ's weekly volatility (11%) has been stable over the past year.
About the Company
EZZ Life Science Holdings Limited provides skin care and consumer health products to retailers and consumers in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as other grocery and on-line retailers.
EZZ Life Science Holdings Fundamentals Summary
|EZZ fundamental statistics|
Is EZZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EZZ income statement (TTM)|
|Cost of Revenue||AU$9.83m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.048|
|Net Profit Margin||9.11%|
How did EZZ perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is EZZ Life Science Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EZZ (A$0.51) is trading above our estimate of fair value (A$0.09)
Significantly Below Fair Value: EZZ is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EZZ's PE Ratio (10.6x) is in line with the Australian Retail Distributors industry average.
PE vs Market: EZZ is good value based on its PE Ratio (10.6x) compared to the Australian market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EZZ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EZZ is good value based on its PB Ratio (2.1x) compared to the AU Retail Distributors industry average (2.3x).
How is EZZ Life Science Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Retail industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EZZ Life Science Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has EZZ Life Science Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: EZZ has high quality earnings.
Growing Profit Margin: EZZ's current net profit margins (9.1%) are higher than last year (8.8%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EZZ's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare EZZ's past year earnings growth to its 5-year average.
Earnings vs Industry: EZZ earnings growth over the past year (28%) underperformed the Retail Distributors industry 28.8%.
Return on Equity
High ROE: EZZ's Return on Equity (20.1%) is considered high.
How is EZZ Life Science Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: EZZ's short term assets (A$11.7M) exceed its short term liabilities (A$1.9M).
Long Term Liabilities: EZZ's short term assets (A$11.7M) exceed its long term liabilities (A$1.3K).
Debt to Equity History and Analysis
Debt Level: EZZ is debt free.
Reducing Debt: EZZ has not had any debt for past 5 years.
Debt Coverage: EZZ has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EZZ has no debt, therefore coverage of interest payments is not a concern.
What is EZZ Life Science Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EZZ's dividend (0.88%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: EZZ's dividend (0.88%) is low compared to the top 25% of dividend payers in the Australian market (5.28%).
Stability and Growth of Payments
Stable Dividend: EZZ is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: EZZ is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: EZZ is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EZZ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Mark Qin, is also known as Qizhou, serves as the Chief Operating Officer at EZZ Life Science Holdings Limited and serves as its Executive Director since October 27, 2020. Mr. Qin serves as an Interim C...
Experienced Board: EZZ's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: EZZ only recently listed within the past 12 months.
EZZ Life Science Holdings Limited's employee growth, exchange listings and data sources
- Name: EZZ Life Science Holdings Limited
- Ticker: EZZ
- Exchange: ASX
- Founded: 2018
- Industry: Distributors
- Sector: Retail
- Market Cap: AU$21.420m
- Shares outstanding: 42.00m
- Website: https://www.ezzlife.com.au
- EZZ Life Science Holdings Limited
- 104 Derby Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:02|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.